Clinical Trials
111 trialsClinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Chidamide Bridging for CAR-T Therapy
Chinese PLA General Hospital
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
HRYZ Biotech Co.
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
Peking University Cancer Hospital & Institute
CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma
Fudan University
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)
Henan Cancer Hospital
Bisantrene Combination for Resistant AML
Sheba Medical Center
Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors
Anhui Provincial Hospital
Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
VICTORY
Melbourne Health
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow University
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
BGI, China
Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma
Chongqing University Cancer Hospital
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia
Shanghai Ming Ju Biotechnology Co., Ltd.
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia
Zhejiang University
Natural Killer(NK) Cell Therapy in r/r AML
Zhejiang University
EBV CAR-T Cells for Nasopharyngeal Carcinoma
The Affiliated Hospital of Xuzhou Medical University
BGT007 Cell Treatment of Nasopharyngeal Carcinoma
The Affiliated Hospital of Xuzhou Medical University
TIL Cells for the Treatment of the Advanced Solid Tumors Patients
Fujian Cancer Hospital
TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors
Fujian Cancer Hospital
Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy
Henan Cancer Hospital
Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL
The First Affiliated Hospital of Soochow University
T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma
Karolinska University Hospital
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors
The First People's Hospital of Lianyungang
Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer
Allife Medical Science and Technology Co., Ltd.
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers
Corregene Biotechnology Co., Ltd
Natural Killer (NK) Cell Therapy for B-Cell Malignancies
Zhejiang University
Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL
The First Affiliated Hospital with Nanjing Medical University
ZFCR/ZBR
Institute of Hematology & Blood Diseases Hospital, China
Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
PETHEMA Foundation
Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Xinqiao Hospital of Chongqing
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma
Xinqiao Hospital of Chongqing
ALIVE
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT
First Affiliated Hospital of Zhejiang University
PALG-AML1/2016
Polish Adult Leukemia Group
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
Hrain Biotechnology Co., Ltd.
Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Xinqiao Hospital of Chongqing
The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer
Shanghai 6th People's Hospital
Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
Xinqiao Hospital of Chongqing
Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Sabz Biomedicals
Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Haploidentical Stem Cell Transplantation in Neuroblastoma
Lund University Hospital
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation
Hebei Senlang Biotechnology Inc., Ltd.
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.